Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential Gemcitabine + Docetaxel vs Gemcitabine + Mitomycin C in BCG-Unresponsive NMIBC
NCT07747740Phase 2Recruiting
- Sponsor
- N.N. Blokhin Russian Cancer Research Center
- Start
- Jul 2026
- Primary completion
- Dec 2029
- Countries
- 1
01
Overview
A Phase 2 trial of docetaxel in non-muscle-invasive bladder cancer (NMIBC), sponsored by N.N. Blokhin Russian Cancer Research Center. Started Jul 2026; status: recruiting.
02
Drugs
docetaxel
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT07747740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07747740.